Arbutus Biopharma Corporation
ABUS
$3.59
$0.010.28%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 29.62% | -2.94% | 4.02% | -1.63% | -5.70% |
| Total Depreciation and Amortization | -29.81% | -4.91% | -1.71% | 3.99% | 8.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.48% | 189.63% | 74.21% | -2.32% | 45.04% |
| Change in Net Operating Assets | -686.52% | 160.50% | 84.48% | 93.13% | 85.97% |
| Cash from Operations | 17.41% | 24.36% | 24.54% | 16.12% | 11.71% |
| Capital Expenditure | 32.81% | 91.18% | 81.94% | 91.59% | 89.34% |
| Sale of Property, Plant, and Equipment | -55.00% | -- | -- | -- | 200.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -47.57% | -51.47% | -55.31% | -24.81% | 196.90% |
| Cash from Investing | -47.61% | -50.64% | -54.80% | -22.96% | 217.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -88.15% | -12.44% | 69.66% | 43.40% | 19.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -88.15% | -12.44% | 69.66% | 43.40% | 19.64% |
| Foreign Exchange rate Adjustments | -400.00% | -500.00% | -296.00% | -128.57% | 105.26% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -171.30% | -338.43% | 323.67% | 321.15% | 276.87% |